EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Exosome-associated cargo is linked to familial Alzheimer's disease-associated phenotypes in vitro

Zahra Motamed, Daniel Heutschi, Gaiser Carine, Laura Suter-Dick

Disease Models & Mechanisms · 2026-11-09

DOI: 10.1242/dmm.052734 ↗
AbstractBibliografische Angaben

Abstract

The propagation of pathological proteins such as tau and amyloid-beta (Aβ) in Alzheimer's disease (AD) is poorly understood. Here, we developed a human-relevant in vitro conditioned medium (CM)-based model using human neural progenitor ReN cells carrying Familial AD (FAD) mutations in amyloid precursor protein (APP Sw/Lo) and presenilin 1 (PSEN1ΔE9). Healthy ReN-derived neurons and astrocytes treated with FAD-CM for nine weeks exhibited AD features, including cellular toxicity, neuro-glial alterations, and mitochondrial dysfunction. Exogenous Aβ42 further induced neuroglial and mitochondrial damage. Exosomes released by FAD cells and -to a lesser extent- by CM-treated healthy cells showed elevated Aβ42/40 ratios. Proteomic analysis also revealed that exosomes from FAD-cells carried a distinct content, including overrepresentation of proteins linked to inflammation, extracellular matrix remodelling, synaptic dysfunction, and Aβ processing, as well as Calmodulin-like protein 3. Moreover, exosomes were actively internalized by healthy cells through an actin-dependent mechanism. In summary, these findings support a model based on FAD-associated APP/PSEN1 mutations in which exosome-associated cargo alongside soluble and non-vesicular factors contribute to the transfer of AD-associated cellular phenotypes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →